Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
Canaccord Genuity 20th Annual MedTech, Diagnostics, Digital Health & Services Forum
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET
Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET
Piper Sandler 38th Annual Healthcare Conference
Participation: Presentation and 1x1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET
Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

4 Growth Stocks to Buy While They’re Still Undervalued

3 of the Best Core Stocks to Own

3 Great New ETFs From 2026

Retirees: 5 Reasons to Consider Index Funds and ETFs


